IPS Statement on the EMA’s Review of Metamizole-Containing Products
The European Medicines Agency (EMA) requested healthcare professionals, patients’ organisations and relevant learned societies to submit comments and data regarding the use of the drug metamizole and associated concerns about the risk of agranulocytosis. The IPS responded to this call which can be viewed here or on the EFIC chapter website.
The outcome of the EMA review can be accessed here https://www.ema.europa.eu/en/medicines/human/referrals/metamizole-containing-medicinal-products-0